MAX BioPharma is at the forefront of developing innovative small molecule lipids aimed at treating serious human diseases, particularly through its pioneering work in Oxysterol Therapeutics®. This novel approach utilizes a unique class of compounds known as oxysterols, which are derived from cholesterol and have been shown to possess therapeutic potential. The company is focused on creating drug candidates that can intervene in debilitating conditions, leveraging a strong intellectual property portfolio to support its research and development efforts.

The company's primary focus areas include the development of OxyFuse-133®, an investigational device designed for spine fusion that promotes bone formation by targeting specialized stem cells. Additionally, MAX BioPharma is advancing Oxy210, an orally bioavailable drug candidate aimed at treating non-alcoholic steatohepatitis (NASH) and metabolic dysfunction associated steatohepatitis (MASH). Oxy210 is characterized by its antifibrotic and anti-inflammatory properties, positioning it as a promising therapeutic option for these conditions. Through these initiatives, MAX BioPharma aims to revolutionize the treatment landscape for serious diseases.

United States

MAX BioPharma is a California-based biotechnology firm developing novel small molecule lipids, referred to as oxysterols, as candidates for therapeutic drugs for debilitating and fatal human diseases. These oxysterol molecules belong to the family of sterols that have the ability to stimulate bone growth, block the growth of cancer cells, and inhibit their ability to metastasize. The company is a pioneer in this new field of Oxysterol Therapeutics® and focused on translating our key science into use for two large unmet medical needs: bone formation (in fracture repair, bone tissue engineering, and osteoporosis) and cancer.

MAX BioPharma

Company Details